Cubosomes in cancer drug delivery: A review

The lyotropic nonlamellar liquid crystalline nanoparticles (LCNs), especially cubosomes are gaining utility and acceptance as a drug delivery system, in diseases like cancer. These cubosomes are highly versatile carriers with promising theranostic efficiency and can be administered via oral, topical, or intravenous modalities. Over the recent years, significant research has facilitated the improvement in the efficacy, preparation, characterization, target selectivity, and controlling drug release profiles of the loaded anticancer bioactive. Nonetheless, its clinical translation has been slow and additionally requires concrete evidence. This review underscores the recent advances and impediments in the development and application of cubosomes against various cancers and discussing the hurdles faced in segueing it into a potential nanotechnological intervention.

Automated summary

Lyotropic nonlamellar liquid crystalline nanoparticles, particularly cubosomes, are being used as drug delivery systems in diseases like cancer. Despite significant advancements in research, clinical translation has been slow and concrete evidence is still needed to support its application.